OTC Markets OTCPK - Delayed Quote USD

Mesoblast Limited (MEOBF)

2.0000

0.0000

(0.00%)

As of January 29 at 3:00:00 PM EST. Market Open.

Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Mesoblast Limited (NASDAQ:MESO) stands against other best ASX stocks to buy according to hedge funds. According to a report by the Australian Bureau of Statistics (ABS) published […]

Insider Monkey 2 hours ago

MSB.AX
Ryoncil® Commercial Launch Update and Product Pipeline

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the U.S. commercial launch of Ryoncil® (remestemcel-L) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline. ”We are committed to making our FDA approved product Ryoncil® available as qu

GlobeNewswire 14 hours ago

MEOBF
0.00%
MESO
+3.18%
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second quarter ended December 31, 2024. ACTIVITY REPORT On December 18, 2024, Ryoncil® (remestemcel-L) became the first mesenchymal stromal cell (MSC) therapy approved by U.S. FDA for any indication.FDA approved Ryoncil® as the first and only therapy for children aged 2 months and

GlobeNewswire 15 hours ago

MEOBF
0.00%
MESO
+3.18%
Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?

We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at where Mesoblast Limited (NASDAQ:MESO) stands against other best Australian stocks to buy now. According to a report by Vanguard published on January 24, Australia’s economy is expected to experience a gradual […]

Insider Monkey 4 days ago

MSB.AX
3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth

As the ASX200 experiences its third consecutive weekly gain, buoyed by a softer US stance on tariffs and calls for lower oil prices and interest rates, investors are keenly observing sectors like Discretionary and Real Estate that have shown robust performance. In this favorable environment, growth companies with substantial insider ownership can offer unique insights into potential earnings expansion, as insiders' vested interests often align closely with shareholder value creation.

Simply Wall St. 7 days ago

MEOBF
0.00%
MESO
+3.18%
ABB.AX
Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock

Multiple insiders secured a larger position in Mesoblast Limited ( ASX:MSB ) shares over the last 12 months. This is...

Simply Wall St. 7 days ago

MEOBF
0.00%
MESO
+3.18%
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

Zacks 27 days ago

MSB.AX

CSTL

CTMX
Exploring 3 High Growth Tech Stocks In Australia

The Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global uncertainties and a weakening Aussie dollar, reflecting broader concerns about economic data and interest rate projections. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovative potential and resilience in fluctuating market conditions.

Simply Wall St. 28 days ago

MEOBF
0.00%
MESO
+3.18%
CLVLF
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Zacks last month

MNPR

ARQT

MSB.AX
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval

Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.

Investor's Business Daily last month

MEOBF
0.00%
MESO
+3.18%
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.

Zacks last month

MSB.AX

INCY
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

This is the only MSC therapy approved in the US for any indication.

Pharmaceutical Technology last month

MSB.AX
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

On Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ:MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents. Ryoncil contains MSCs, a type of cell that can have various roles in the body and can differentiate into multiple other types of cell

Benzinga last month

MSB.AX
Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024. The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies clas

GlobeNewswire last month

MEOBF
0.00%
MESO
+3.18%
DREAM-HF trial sheds positive light on Revascor for ischemic HF

GlobalData believes that the study could be of high clinical value to cardiologists.

Clinical Trials Arena last month

MSB.AX

GLDAF
3 ASX Growth Companies With Insider Ownership Up To 38%

In the last week, the Australian market has been flat, but it has shown impressive growth over the past year with a 16% increase and an annual earnings growth forecast of 13%. In this context, identifying growth companies with significant insider ownership can be particularly appealing as it often indicates confidence from those closest to the business in its future prospects.

Simply Wall St. last month

VSL.AX

LINRF

MEOBF
0.00%
Mesoblast’s Revascor Therapy Shows Promise in Heart Failure

Mesoblast (MESO) has released an update. Mesoblast’s allogeneic cell therapy, Revascor, has shown promising results in improving survival and reducing major cardiovascular events in high-risk ischemic heart failure patients with inflammation, according to a recent study. The therapy significantly lowered the risk of cardiovascular death and major adverse cardiovascular events, highlighting its potential as a disease-modifying treatment. This breakthrough could position Mesoblast favorably in the

TipRanks last month

MEOBF
0.00%
MESO
+3.18%
Exploring High Growth Tech Stocks in Australia December 2024

As the Australian market experiences a modest uptick with the ASX200 rising by 0.3% to 8,488 points, the IT sector stands out as a strong performer, climbing by 1.1%, amidst broader economic indicators suggesting potential volatility and constraints in the coming year. In this environment, identifying high-growth tech stocks requires careful consideration of their ability to thrive in dynamic conditions and leverage technological advancements to sustain momentum within an evolving market...

Simply Wall St. last month

MEOBF
0.00%
MESO
+3.18%
FNCHF
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Reva

GlobeNewswire last month

MEOBF
0.00%
MESO
+3.18%
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapyNEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure (EJHF), which reports that a single intramyocardial injection of the

GlobeNewswire last month

MEOBF
0.00%
MESO
+3.18%

Performance Overview

Return	MEOBF	S&P/ASX 200 [XJO]
YTD	+8.70%	+4.57%
1-Year	+1,076.47%	+11.09%
3-Year	+122.22%	+22.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mesoblast Limited (MEOBF)

Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?

3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth

Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Exploring 3 High Growth Tech Stocks In Australia

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast to be Added to Nasdaq Biotechnology Index

DREAM-HF trial sheds positive light on Revascor for ischemic HF

3 ASX Growth Companies With Insider Ownership Up To 38%

Mesoblast’s Revascor Therapy Shows Promise in Heart Failure

Exploring High Growth Tech Stocks in Australia December 2024

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Performance Overview